A Phase 4 interventional study of Sumavel DosePro and Sumatriptan in Migraine, sponsored by Zogenix, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Zogenix, Inc. (part of UCB S.A.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing sumatriptan in Migraine Disorders — none open to participants now, none under way, none of them phase 3. Sumatriptan · Migraine Disorders.
Among the 42 studies testing sumatriptan in Migraine Disorders, this one is the 15th largest by enrollment, is one of 6 that started in 2009, is one of 7 in phase 4, and was the 20th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →None of the 42 studies testing sumatriptan in Migraine Disorders is open now. The open studies under Migraine Disorders, anywhere →
Sumatriptan: first FDA approval 1992 (IMITREX STATDOSE (AUTOINJECTOR)). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 246 is above the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 74 across the 42 interventional studies. Of the 40 that completed or were terminated, 20 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Zogenix, Inc., one of the names counted as UCB S.A.. Under that name alone:
Zogenix, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
UCB S.A. has 3 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 42 studies testing sumatriptan in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.
Single arm, open-label, multicenter study to evaluate the treatment satisfaction, treatment confidence, and subject preference for Sumavel DosePro in adult subjects diagnosed with migraines and currently treated with triptans. Subjects will treat up to 4 migraines over a 60 day period and complete migraine diaries and questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm study (Sumavel DosePro)
Device: Sumavel DosePro · Drug: Sumatriptan
Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
Also known as: Sumavel DosePro (Sumatriptan injection)
Overall Treatment Satisfaction at the End of the Treatment
Overall participant satisfaction with migraine treatment Sumavel DosePro was measured using the Patient Perception of Migraine Questionnaire-Revised (PPMQ-R), question 3c "Overall satisfaction". The PPMQ-R scores (scale ranges from 1-7 with 1=very satisfied) were transformed to a 0-100 scale with higher scores indicating a higher level of treatment satisfaction (100=very satisfied).
Time frame: At the end of the treatment (after 4 migraines or 60 days, whichever came first)
Treatment Preference
Number of participants preferring Sumavel DosePro compared to their pre-study migraine treatment (Prefer Sumavel DosePro vs. No Preference or Prefer Other Treatment).
Time frame: After 4 migraines or 60 days whichever came first
Treatment Confidence
Number of subjects who indicated they were confident or very confident in treating repeated migraine attacks with Sumavel DosePro at end of treatment.
Time frame: After 4 migraines or 60 days whichever came first
Recruitment period occured from November, 2009 to February, 2010 at 22 US medical clinics.
| Milestone | Sumavel DosePro |
|---|---|
| Started | 246 |
| Safety population | 242 |
| Per-protocol population | 212 |
| Completed | 220 |
| Not completed | 26 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Adverse event | 4 |
| Withdrew: Non-compliance | 2 |
| Withdrew: Subject decision | 13 |
| Withdrew: Did not treat due to work situation | 1 |
Overall participant satisfaction with migraine treatment Sumavel DosePro was measured using the Patient Perception of Migraine Questionnaire-Revised (PPMQ-R), question 3c "Overall satisfaction". The PPMQ-R scores (scale ranges from 1-7 with 1=very satisfied) were transformed to a 0-100 scale with higher scores indicating a higher level of treatment satisfaction (100=very satisfied).
| units on a scale | Sumavel DosePro |
|---|---|
| Overall Treatment Satisfaction at the End of the Treatment | 73.7 ± 29.08 |
Number of participants preferring Sumavel DosePro compared to their pre-study migraine treatment (Prefer Sumavel DosePro vs. No Preference or Prefer Other Treatment).
| participants | Sumavel DosePro |
|---|---|
| Treatment Preference | 74 |
Number of subjects who indicated they were confident or very confident in treating repeated migraine attacks with Sumavel DosePro at end of treatment.
| participants | Sumavel DosePro |
|---|---|
| Treatment Confidence | 137 |
Collected over 60 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sumavel DosePro | 0/242 (0%) | 0/242 (0%) | 136/242 (56.2%) |
| Event | Sumavel DosePro |
|---|---|
| Administrative site conditionsGeneral disorders | 99/242 |
| NauseaGastrointestinal disorders | 18/242 |
| DizzynessNervous system disorders | 17/242 |
| ParesthesiaNervous system disorders | 14/242 |
| Muscle tightnessMusculoskeletal and connective tissue disorders | 14/242 |
| FlushingVascular disorders | 14/242 |
| SomnolenceNervous system disorders | 13/242 |
| Dry mouthGastrointestinal disorders | 12/242 |
Baseline Characteristics refer to the Safety Population including all participants who received at least one dose of Sumavel DosePro.
| Age, Categorical(Participants) | Sumavel DosePro |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 242 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Sumavel DosePro |
|---|---|
| Female | 196 |
| Male | 46 |
| Region of Enrollment(Participants) | Sumavel DosePro |
|---|---|
| United States | 242 |
Ran from Nov 2009 to primary completion in Apr 2010, 5 months.
Results were first posted in Dec 2011, 1 year 7 months after primary completion.
Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 5 months is below that.
Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sumatriptan